Athersys Announces Expansion of Collaboration With Healios
Healios receives rights to develop and commercialize additional indications and Athersys receives $20 million in license fees, plus potential milestones payments and royalties
Discussions extended for China and other rights
CLEVELAND, Ohio, June 07, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that it has entered into an agreement with HEALIOS K.K. ("Healios") to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment of acute respiratory distress syndrome ("ARDS") and of MultiStem cells used in combination with iPSC-derived cells for the treatment of certain organs. Healios also received an exclusive global license to develop and commercialize MultiStem cells, either as a standalone therapy or in combination with retinal pigmented epithelial ("RPE") cells for certain ophthalmological indications, and an expansion of its license to use Athersys technology to support its organ bud programs to include other transplantation areas. In exchange, Athersys receives $20 million in license fees, comprising $10 million paid from an escrow account established with the letter of intent signed in March 2018 and four installments of $2.5 million each to be paid in this and the next three quarters.
As part of the agreement, Athersys may also receive up to approximately $360 million in aggregate development and commercialization milestones for the licensed programs, as well as tiered double-digit royalties on MultiStem therapies developed for ARDS, and single-digit royalties for other licensed products. Under the terms of the agreement, Healios will also receive a credit of $10 million to be used against certain future development milestones and a right of first negotiation to broaden the field and territory related to MultiStem cells used in combination with iPSC-derived cells.
Also as part of the agreement, Healios has been granted a right of first negotiation regarding an exclusive option for a license to develop and commercialize MultiStem therapy for certain indications in China, and the potential inclusion of an additional indication to the Japan license.
"We are excited about completing this collaboration expansion with Healios," commented Dr. Gil Van Bokkelen, Chairman and CEO of Athersys. "It creates exciting opportunities in meaningful therapeutic areas where there is substantial unmet medical need and tangible value for both companies, building off of the work already conducted by Athersys in certain areas, including ARDS."
In association with Healios' recent equity investment and the expanded collaboration, Dr. Hardy Kagimoto, CEO of Healios, has been nominated for election to the Athersys Board of Directors at the next scheduled annual stockholders' meeting on June 18, 2018.
MultiStem® cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage. MultiStem therapy's potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent safety profile demonstrated in clinical studies, MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.
Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "suggest," "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face that could cause actual results to differ materially from those implied by forward-looking statements are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, such as the uncertainty regarding regulatory approval and market acceptance of our product candidates and our ability to generate revenues, including MultiStem for the treatment of ischemic stroke, acute myocardial infarction, spinal cord injury and acute respiratory distress syndrome and other disease indications, including graft-versus-host disease. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: our ability to work with Healios to reach an agreement on an option for China; the success of our collaboration with Healios and others, including our ability to reach milestones and receive milestone payments, and whether any products are successfully developed and sold so that we earn royalty payments; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our collaborators' ability to continue to fulfill their obligations under the terms of our collaboration agreements; the success of our efforts to enter into new strategic partnerships or collaborations and advance our programs; our ability to raise additional capital; results from our MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial and the TREASURE trial in Japan; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials within the expected time frame or at all; changes in external market factors; changes in our industry's overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
William (B.J.) Lehmann
President and Chief Operating Officer
Tel: (216) 431-9900
Corporate Communications & Investor Relations
Tel: (216) 431-9900
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Athersys, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
2018 Online Journalism Awards finalists and James Foley Award recipient announced14.8.2018 19:29 | Pressemelding
WASHINGTON, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Finalists for the 2018 Online Journalism Awards, representing a wide range of local and international media, nonprofit, public, academic and emerging technology organizations, were announced today by the Online News Association. Thirteen of the awards come with $58,500 in prize money, courtesy of John S. and James L. Knight Foundation, the Gannett Foundation , the University of Florida College of Journalism and Communications and Journalism 360. These awards honor data journalism, visual digital storytelling, investigative journalism, immersive storytelling, public service, technical innovation, student journalism and general excellence. This year’s awards introduced a new category for Excellence in Collaboration and Partnerships, honoring newsrooms and companies who formed innovative partnerships or collaborations to cover a topic or story with a digital focus. In addition, the General Excellence category now has a micro size group for new
Pinnacle Studio 22 Ultimate Amps Up Video Editing with New Pro-inspired Features14.8.2018 15:11 | Pressemelding
New Three- and Four-Point Editing, Color Grading, and MultiCam Capture Lite deliver advanced video editing options to bring your videos even closer to pro OTTAWA, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Introducing Pinnacle Studio™ 22 Ultimate, Pinnacle’s flagship video editing software that offers powerful features, precise editing controls, and premium effects to create eye-catching video projects with professional flair. With new Three- and Four-Point Editing, Color Grading, dynamic Split Screen videos, MultiCam Capture Lite, and more, Pinnacle Studio 22 Ultimate gives users a complete collection of pro-inspired features to express their unique vision and achieve stunning results. “Pinnacle Studio Ultimate is the go-to choice for users looking for true creative control and a sophisticated editing experience from a consumer video editor,” said Michel Yavercovski, Senior Director of Product Management for Pinnacle. “With the latest version, we’re pushing this even further with a pro-inspire
Keesal, Young & Logan and Mitratech Announce TAP Workflow Automation Partnership with the Launch of Keesal Propulsion Labs14.8.2018 15:02 | Pressemelding
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Keesal, Young & Logan (KYL) and Mitratech announced today the TAP Workflow Automation partnership to help a greater number of legal professionals quickly implement standardization and compliance across a wide range of legal processes, starting with KYL’s own clients. But it doesn’t stop there. The partnership has resulted in the launch of Keesal Propulsion Labs (KPL) designed to position KYL as an extension of their clients’ teams — helping them to expand and connect their tech stack to solve complex legal and business process challenges. “The goal of KPL is to break down the walls between solution providers, law firms and clients so they can operate as one unit and transform legal operations into a center of excellence that drives innovation across the entire organization,” said Justin Hectus, CIO/CISO at KYL. “By creating cross-ecosystem collaboration, we are uniting people, processes, and compliance, to help mitigate risk and position the
Meltwater launches data science platform Fairhair.ai to tame real-time market signals found in world’s online data14.8.2018 15:00 | Pressemelding
AI-powered platform democratises analytics of forward-looking indicators based on insights from the outside, known as Outside Insight SAN FRANCISCO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- In the quest to become data-driven, companies are increasingly investing in Business Intelligence software to gain a competitive advantage. Yet the insights generated by those tools are mostly fuelled by data from within a company’s walls, instead of the real-time market signals found externally online – from consumer opinions to corporate filings. This outside data can unlock key indicators about an industry or competitor, but harnessing the volume and variety of global data is a time-intensive task. And although advances in artificial intelligence have made it easier to capture and analyse this data to create powerful insights, most commercial AI tools are one-size-fits-all models with limited capabilities. That’s why Meltwater – a pioneer of media intelligence and curator of the world’s most diverse col
Gratomic Provides Update on Perpetuus Graphene Development Program14.8.2018 14:00 | Pressemelding
TORONTO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. (“GRAT” or the “Company”) (TSX-V: GRAT) (FRANKFURT:CB81, WKN:A2JAP3). Gratomic, is pleased to provide an update on its previously announced Graphene development program primarily targeted towards elastomer and polymer tire markets, launched with its European partner, Perpetuus Carbon Technologies Limited (“Perpetuus”), a wholly owned subsidiary of Perpetuus Advanced Materials. As disclosed by Gratomic on April 22, 2018, Perpetuus and Gratomic executed a letter of collaboration pursuant to which Perpetuus undertook to build three specialized process tooling chambers (“Chambers”) to be used solely for processing Graphite from Gratomic’s Aukam Graphite mine in Namibia. The first of such Chambers has passed the testing phase and is ready to process the Aukam sourced Graphite, the second Chamber is presently under construction with the third to follow immediately thereafter. Photos accompanying this announcement are available at http:
CrownBio Expands Genetically Engineered Model Selection Via Strategic Alliance with Shanghai Model Organisms Center (SMOC)14.8.2018 14:00 | Pressemelding
Alliance enables researchers to access thousands of GEMMs SAN DIEGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has entered a strategic alliance with Shanghai Model Organisms Center (SMOC) to exclusively license and commercialize SMOC’s comprehensive collection of genetically engineered models, including proprietary transgenic and reporter models for oncology, cardiovascular and immunology research. SMOC leverages expertise in several gene editing technologies to develop conventional knockout (KO), conditional KO, transgenic knock-in and humanized models. These capabilities are now exclusively available to CrownBio’s international clients for custom model generation, breeding, IVF, rapid expansion and re-derivation capabilities. “The strategic alliance with SMOC helps CrownBio become a leading global provid
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom